Treating type 2 diabetes: Incretin mimetics and enhancers

Therapeutic Advances in Cardiovascular Disease

Volumn 3, Issue 5, 2009, Pages 387-395

  Nori Janosz, Katherine E ^a   Zalesin, Kerstyn C ^a   Miller, Wendy M ^a   Mccullough, Peter A ^b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

Cardiovascular risk reduction; Dipeptidyl peptidase 4 (DPP 4) inhibitors; Gastric inhibitory peptide (GIP); Glucagon like peptide (GLP 1); Incretin enhancers; Incretin mimetics; Incretins; Resolution of diabetes; Treatment of diabetes; Type 2 diabetes mellitus; Weight loss

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 8 (3 AMINO 1 PIPERIDINYL) 7 (2 BUTYNYL) 3 METHYL 1 (4 METHYL 2 QUINAZOLINYLMETHYL)XANTHINE; ALBIGLUTIDE; ALOGLIPTIN; ANTIDIABETIC AGENT; BIPHASIC INSULIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DUTOGLIPTIN; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; INCRETIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; ONGLYZA; PHX 1149; PIOGLITAZONE; PLACEBO; R 1579; R 1583; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TASPOGLUTIDE; UNCLASSIFIED DRUG; VICTOZA; VILDAGLIPTIN;

ADD ON THERAPY; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; RISK REDUCTION; SIDE EFFECT; SNEEZING; STOMACH BYPASS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; TREATMENT OUTCOME;

EID: 70350026679     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944709341377     Document Type: Review

References (43)

1. Abraham, E.J., Leech, C.A., Lin, J.C., Zulewski, H., Habener, J.F. et al. (2002) Insulinotropic hormone glucagons-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 143: 3152.
2. ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560.
3. Amori, R.E., Lau, J. and Pittas, A.G. ( 2007) Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298: 194.
4. Aschner, P., Kipnes, M.S., Lunceford, J.K., Sanchez, M., Mickel, C., Williams-Herman, D.E. et al. (2006) Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29: 2632-2637.
5. Blase, E., Deng, W., Walsh, B., Fineman, M. and Rhodes, C. ( 2008) Intranasal administration of exenatide in patients with type 2 diabetes: pharmokinetics, pharmodynamics, safety, and tolerability. Program and abstracts of the American Diabetes Association (ADA) 68th Scientific Sessions, 6-10 June 2008, San Francisco, p. 484.
6. Bjerre, K.L., Moller Knudsen, S., Wilken, M. et al. (2005) Plasma protein binding of NN2211, a long-acting derivative of GLP-1, is important for its efficacy. Diabetes 52(Suppl. 1): 321-322.
7. Blonde, L., Klein, E.J., Han, J., Zhang, B., Mac, S.M., Poon, T.H. et al. (2006) Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8: 436-447.
8. Blonde, L., Rosenstock, J., Sesti, G., Schmidt, W.E., Montanya, E., Brett, J.H. et al. (2008) Liraglutide: superior glycemic control versus exenatide when added to metformin and / or sulphonylurea in type 2 diabetes (LEAD-6). Poster presented at the Canadian Diabetes Association Congress, 15-18 October, Montreal, Canada.
9. Carr, M.E. ( 2001) Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 15: 44-54.
10. Charbonnel, B., Karasik, A., Liu, J., Wu, M. and Meininger, G. ( 2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformon therapy in patients with type 2 diabetes inadequetly controlled on metformin alons. Diabetes Care 29: 2638-2643.
11. Chia, C.W. and Egan, J.M. ( 2008) Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrin Metab 93: 3703-3716.
12. Croxtall, J.D. and Keam, S.J. ( 2008) Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 68 (16): 2387-2409.
13. Davis, S.N., Johns, D., Maggs, D., Xu, H., Northrup, J.H., Brodows, R.G. et al. (2007) Exploring the subsitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 30: 2767.
14. de Fronzo, R.A., Ratner, R.E., Han, J., Kim, D.D., Fineman, M.S. and Baron, A.D. ( 2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28: 1092.
15. de Leon, D.D., Crutchlow, M.F., Nina Ham, J.-Y. and Stoffers, D.A. ( 2006) Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int J Biochem Cell Biol 38: 845-859.
16. Drucker, D.J., Buse, J.B. and Taylor, K. ( 2008) Exenatide once weekly results in significantly greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetes. Program and abstracts of the American Diabetes Association (ADA) 68th Scientific Session, 6-10 June, California, Abstract 107-OR.
17. Goldstein, B.J., Feinglos, M.N., Lunceford, J.K., Johnson, J. and Williams-Herman, D.E. ( 2007) Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30: 1979-1987.
18. Handelsman, Y. ( 2008) Treating diabetes with incretin hormones - clinical experience. PER 5: 897-903.
19. Jellinger, P.S., Davidson, J.A., Blonde, L., Einhorn, D., Grunberger, G., Handelsman, Y. et al. (2007) Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE / AACE Diabetes Road Map Task Force. Endocr Pract 13: 260-268.
20. Laferrère, B., Teixeira, J., McGinty, J., Tran, H., Egger, J.R., Colarusso, A. et al. (2008) Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 93: 2479-2485.
21. Litwin, S.E. ( 2006) The growing problem of obesity and the heart: the plot ‘thickens’. J Am Coll Cardiol 47: 617-619.
22. Meier, J.J. ( 2008) Beta cell mass in diabetes: a realistic therapeutic target ? Diabetologia 51: 703-713.
23. Miller, W.M., Nori Janosz, K.E., Yanez, J. and McCullough, P.A. ( 2005) Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease. Expert Rev Cardiovasc Ther 3: 743-759.
24. McIntyre, N., Holdsworth, C.D. and Turner, D.S. ( 1964) New interpretation of oral glucose tolerance. Lancet 4: 20-21.
25. Nathan, D.M. ( 2007) Finding new treatments for diabetes - how many, how fast. how good? N Engl J Med 356: 437-440.
26. Nauck, M.A., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A. et al. (2007) A comparision of twice-daily exenatide and biphasic insulin asprt in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50: 259.
27. Nauck, M., Frid, A., Hermansen, K., Shah, N.S., Tankova, T., Mitha, I.H. et al. (2008) Efficacy and safety comparison of Liraglutide, Glimepiride, and Placebo, all in combination with metformin in type 2 diabetes. Diabetes Care 32: 84-90.
28. Nielsen, L.L., Young, A.A. and Parks, D.G. ( 2004) Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 117: 77-88.
29. Nikolaidis, L.A., Mankad, S., Sokos, G.G., Miske, G., Shah, A., Elahi, D. et al. (2004) Effects of glucagons-like-peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109: 962-965.
30. Nystrom, T., Gutniak, M.K., Zhang, Q., Zhang, F., Holst, J.J., Ahrén, B. et al. (2004) Effects of glucagons-like-peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287: E1209-E1215
31. Pratley, R.E. ( 2008) Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape Journal 10: 171.
32. Ratner, R.E., Maggs, D., Nielsen, L.L., Stonehouse, A.H., Poon, T., Zhang, B. et al. (2006) Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 8: 419.
33. Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D. and Khatami, H. ( 2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49: 2564-2571.
34. Rodbard, H.W., the AACE Diabetes Mellitus Clinical Practice Guidelines Task Force (2007) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13 (Suppl. 1): 3-68.
35. Rosenstock, J., Brazg, R., Andryuk, P.J., Lu, K. and Stein, P. ( 2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28: 1556-1568.
36. Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F.L., Powe, N.R. et al. (2004) Meta-analysis:glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141: 421.
37. Tominaga, M., Eguchi, H., Manaka, H., Igarashi, K., Kato, T. and Sekikawa, A. ( 1999) Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22: 920-924.
38. Toft-Nielson, M.B., Darnholt, M.B., Madsbad, S., Hilsted, L.M., Hughes, T.E., Michelsen, B.K. et al. (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86: 3717-3723.
39. Turner, R.C., Cull, C.A., Frighi, V., Holman, R.R.; UK Prospective Diabetes Study Group (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UJPDS 49). JAMA 281: 2005-2012.
40. Vilsboll, T., Zdravkovic, M. and Le-Thi, T. ( 2006) Beneficial effects of the GLP-1 analogue liraglutide on blood pressure and cardiovascular risk markers in subjects with type 2 diabetes. Diabetic Med 23(Suppl. 4): 696.
41. Vilsboll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J.P. et al. (2007) Liraglutide, a long-acting human glucagon-like peptide -1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30: 1608-1610.
42. Williams-Herman, D. ( 2008) Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord 8: 14.
43. Williamson, D.F., Thompson, T.J., Thun, M., Flanders, D., Pamuk, E., Byers, T. et al. (2000) Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 23: 1499-1505.